Modeling common Alzheimer's disease with high and low polygenic risk in human iPSC: A large-scale research resource.

IF 5.9 2区医学 Q1 CELL & TISSUE ENGINEERING

Stem Cell Reports Pub Date : 2025-06-21 DOI:10.1016/j.stemcr.2025.102570

Emily Maguire, Jincy Winston, Sarah H Ellwood, Rachel O'Donoghue, Bethany Shaw, Atahualpa Castillo Morales, Samuel Keat, Alexandra Evans, Rachel Marshall, Lauren Luckcuck, Laura Brown, Elisa Salis, Ganna Leonenko, Nicola Denning, Nicholas D Allen, Valentina Escott-Price, Caleb Webber, Philip R Taylor, Rebecca Sims, Sally A Cowley, Julie Williams, Sarah M Carpanini, Hazel Hall-Roberts

{"title":"Modeling common Alzheimer's disease with high and low polygenic risk in human iPSC: A large-scale research resource.","authors":"Emily Maguire, Jincy Winston, Sarah H Ellwood, Rachel O'Donoghue, Bethany Shaw, Atahualpa Castillo Morales, Samuel Keat, Alexandra Evans, Rachel Marshall, Lauren Luckcuck, Laura Brown, Elisa Salis, Ganna Leonenko, Nicola Denning, Nicholas D Allen, Valentina Escott-Price, Caleb Webber, Philip R Taylor, Rebecca Sims, Sally A Cowley, Julie Williams, Sarah M Carpanini, Hazel Hall-Roberts","doi":"10.1016/j.stemcr.2025.102570","DOIUrl":null,"url":null,"abstract":"<p><p>Common forms of Alzheimer's disease (AD) are complex and polygenic. We have created a research resource that seeks to capture the extremes of polygenic risk in a collection of human induced pluripotent stem cell (iPSC) lines from over 100 donors: the IPMAR Resource (iPSC Platform to Model Alzheimer's Disease Risk). Donors were selected from a large UK cohort of 6,000+ research-diagnosed early or late-onset AD cases and elderly cognitively healthy controls, many of whom have lived through the age of risk for disease development (>85 years). We include iPSC with extremes of global AD polygenic risk (high-risk late-onset AD: 34; high-risk early-onset AD: 29; low-risk control: 27) as well as those reflecting complement pathway-specific genetic risk (high-risk AD: 9; low-risk controls: 10). All iPSC have associated clinical, longitudinal, and genetic datasets and will be available through collaboration or from cell (EBiSC) and data (DPUK) repositories.</p>","PeriodicalId":21885,"journal":{"name":"Stem Cell Reports","volume":" ","pages":"102570"},"PeriodicalIF":5.9000,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem Cell Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.stemcr.2025.102570","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}

引用次数: 0

Abstract

Common forms of Alzheimer's disease (AD) are complex and polygenic. We have created a research resource that seeks to capture the extremes of polygenic risk in a collection of human induced pluripotent stem cell (iPSC) lines from over 100 donors: the IPMAR Resource (iPSC Platform to Model Alzheimer's Disease Risk). Donors were selected from a large UK cohort of 6,000+ research-diagnosed early or late-onset AD cases and elderly cognitively healthy controls, many of whom have lived through the age of risk for disease development (>85 years). We include iPSC with extremes of global AD polygenic risk (high-risk late-onset AD: 34; high-risk early-onset AD: 29; low-risk control: 27) as well as those reflecting complement pathway-specific genetic risk (high-risk AD: 9; low-risk controls: 10). All iPSC have associated clinical, longitudinal, and genetic datasets and will be available through collaboration or from cell (EBiSC) and data (DPUK) repositories.

查看原文本刊更多论文

人类iPSC中高、低多基因风险的常见阿尔茨海默病建模：大规模研究资源。

阿尔茨海默病（AD）的常见形式是复杂和多基因的。我们已经创建了一个研究资源，旨在捕捉来自100多个捐赠者的人类诱导多能干细胞（iPSC）系的极端多基因风险：IPMAR资源（iPSC模型阿尔茨海默病风险平台）。捐赠者是从英国6000多名研究诊断的早发性或晚发性AD病例和老年认知健康对照者中挑选出来的，其中许多人已经度过了疾病发展的风险年龄（85岁左右）。我们纳入了全球AD多基因风险极端的iPSC(高风险晚发性AD: 34；高危早发性AD: 29；低风险对照：27)，以及反映补体途径特异性遗传风险(高风险AD: 9；低风险控制：10)。所有iPSC都有相关的临床、纵向和遗传数据集，并将通过协作或从细胞（EBiSC）和数据（DPUK）存储库中获得。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Stem Cell Reports CELL & TISSUE ENGINEERING-CELL BIOLOGY

CiteScore

10.50

自引率

1.70%

发文量

200

审稿时长

28 weeks

期刊介绍： Stem Cell Reports publishes high-quality, peer-reviewed research presenting conceptual or practical advances across the breadth of stem cell research and its applications to medicine. Our particular focus on shorter, single-point articles, timely publication, strong editorial decision-making and scientific input by leaders in the field and a "scoop protection" mechanism are reasons to submit your best papers.